SHIRE PHARMACEUTICAL DEVELOPMENT LIMITED
Company Information
- Company Number
- 02486738
- Registered Address
- 1 Kingdom Street, London, United Kingdom, W2 6BD
- Status
- Dissolved
- Employee Count
- 5
- Turnover
- £9,889,000
- EBITDA
- £300,000
Additional Details
- Website
- https://focusongaucher.co.uk
- Company Type
- Private limited Company
- Incorporated On
- 29 March 1990
- Nature of Business
- 72190 - Other research and experimental development on natural sciences and engineering
- Industries
- Professional Services
- Region
- London
Time to Pay
Payment Timeline
Payment Features
Company Review
Trend Analysis
The average time taken for SHIRE PHARMACEUTICAL DEVELOPMENT LIMITED to pay invoices to suppliers has fluctuated over the past three periods, with a decrease in 2020 compared to previous years. The percentage of invoices paid within 30 days has also fluctuated, with an increase in the most recent period.
Volatility Analysis
The volatility in the average time taken to pay invoices has been relatively high, with changes ranging from 7 to 27 days. The volatility in the percentage of invoices paid within 30 days has been lower, with changes ranging from 4 to 11%.
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Apr 2020 - 30 Sept 2020 | 29 Oct 2020 | 57 | 61% | 21% | 18% | 15% |
| 01 Jan 2020 - 31 Mar 2020 | 24 Apr 2020 | 30 | 87% | 9% | 4% | 6% |
| 01 Jul 2019 - 31 Dec 2019 | 25 Feb 2020 | 32 | 73% | 23% | 4% | 8% |
| 01 Jan 2019 - 30 Jun 2019 | 30 Jul 2019 | 39 | 71% | 19% | 10% | 25% |
| 01 Jul 2018 - 31 Dec 2018 | 28 Jan 2019 | 40 | 63% | 17% | 20% | 53% |
| 01 Jan 2018 - 30 Jun 2018 | 30 Jul 2018 | 30 | 74% | 17% | 9% | 44% |
Payment Time Trends
Payment Distribution Trends
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
Terms are applied from invoice receipt date
Were there any changes to the standard payment terms in the reporting period?
No
Any other information about payment terms
N/A
Maximum contractual payment period agreed
60
Dispute Resolution Process
Takeda Business Solutions (TBS), is responsible for maintaining supplier information, PO processing, invoice processing and payments. Please note the following important points about contacting us.We operate a ticketing system to ensure all queries are recorded and responded to within agreed timelines.All new queries will be assigned a Case Number and [ref: XXX]These numbers should be quoted on all replies to TBS. You’ll find it in the subject line of our auto-reply. Please use this case number if following up on your email or reply directly to our case email. Query handing email address : accountspayableEU@shire.com
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
✅
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Company Summary
SHIRE PHARMACEUTICAL DEVELOPMENT LIMITED is a leading pharmaceutical company based in the UK. They are committed to providing innovative and sustainable healthcare solutions to improve the lives of patients worldwide.
Their sustainability program focuses on reducing their environmental impact and promoting ethical and responsible business practices. This includes initiatives such as reducing carbon emissions, managing waste and promoting diversity and inclusion within their workforce.
The company offers a wide range of products and services, including prescription medicines, over-the-counter treatments and medical devices. They specialize in areas such as rare diseases, neuroscience, and immunology.
Key people at SHIRE PHARMACEUTICAL DEVELOPMENT LIMITED include CEO Flemming Ornskov, who has over 25 years of experience in the pharmaceutical industry. He is supported by a team of experienced executives and scientists who are dedicated to driving the company's success.
To contact SHIRE PHARMACEUTICAL DEVELOPMENT LIMITED, you can visit their website at www.shire.com. Their registered office address is 300 Shire Way, Lexington, MA 02421, USA.
In conclusion, SHIRE PHARMACEUTICAL DEVELOPMENT LIMITED is a reputable pharmaceutical company with a strong commitment to sustainability and improving healthcare outcomes. With a diverse range of products and a team of experienced leaders, they continue to make a significant impact in the pharmaceutical industry.
